The safety technology company will use the capital to advance product development and field testing for its wearable rescue indicators.
"We are thrilled to welcome TrapDtek to our portfolio. Hunter has tackled a human problem with a compelling combination of deep technology and user-centric design. By turning complex radio-frequency technology into a simple physical product, TrapDtek equips emergency responders with a powerful tool in difficult environments. The platform offers strong potential across rescue and broader safety-critical applications, and we look forward to supporting the team through their next phase of growth."
Winfred reads them overnight, pulls out the facts, checks them against Companies House and files them. It was built by C8VA, who do the same kind of work for other businesses: turning messy, unstructured material into something you can search, count and rely on.
Bullhound Capital led the Series C financing, which stands as Europe's largest private quantum funding round.
"Globally, it represents a clear shift in the market from long-term promise to near-term delivery in quantum computing. For OQC, this gives us the capital to scale internationally, advance our technology roadmap, and meet increasing demand from customers seeking secure, scalable access to quantum computing infrastructure."
The London deeptech startup secured backing from Ascension Ventures to scale its voice biometrics technology.
"Voice is the last unencrypted frontier in enterprise security, and generative AI just made the stakes existential. Voxmind’s physics-based approach, on-device deployment, and existing OEM footprint give them a structural advantage that’s very difficult to replicate. Excited to lead this round and back the team as they scale."
THENA Capital led the seed round to help advance Zonova toward major OEM partnerships and international deployment.
"This funding marks a defining moment for Zonova. We founded the company with the belief that infection prevention in medical devices needed a fundamentally new approach, one that moves beyond coatings, antibiotics, and short term fixes. Our technology has the potential to redefine how medical devices are designed globally by embedding antimicrobial protection directly into the material itself. THENA Capital immediately understood both the scale of the clinical problem and the magnitude of the commercial opportunity. The THENA team brings an exceptional combination of scientific depth, strategic insight, and operational ambition that is incredibly rare in venture. We are thrilled to have them leading this round and joining us as we scale toward major OEM partnerships and international deployment."
